We are Sorry, This Page doesn't Exist
JPMorgan survey "broadly positive" on Eli Lilly Alzheimer"s drug
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Lilly"s stock is down after sharing additional clinical data about its Alzheimer"s disease drug candidate
ShaShares of Eli Lilly & Co. were down 5.2% in premarket trading on Monday, two days after the drug maker said additional clinical-trial data reinforced the role its experi.....»»
Eli Lilly falls 9% after its Alzheimer"s drug data underwhelms Wall Street
A successful Alzheimer's drug has been viewed as the holy grail in biotech, as it would combat a devastating disease that has a large unmet need. The logo of Lilly is seen on a wall of the Lilly France co.....»»
New data on Eli Lilly"s experimental Alzheimer"s drug backs a hotly debated scientific theory, but shows mixed benefits for patients
Eli Lilly's treatment reduced a harmful substance in the brains of patients with Alzheimer's disease and slowed their rate of cognitive decline. Patients sit inside the Alzheimer's Foundation in Mexico City Thomson Reuters Eli Lilly's.....»»
Eli Lilly rockets 14% after experimental Alzheimer"s drug slows rate of decline in trial
The drug slowed t.....»»
Biogen"s stock is up 5% after Lilly reports positive data from an Alzheimer"s study
Shares of Biogen Inc. gained 5.6% in trading on Monday after another drugmaker shared positive clinical data about an experimental Alzheimer's disease treatment that is similar to a Biogen therapy under review by the Food and Drug A.....»»
Lilly"s stock jumps 15% after experimental Alzheimer"s drug shows it can slow cognitive decline
Shares of Eli Lilly & Co. gained 15.4% in premarket trading on Monday after the drugmaker said its experimental Alzheimer's disease.....»»
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly
Zacks.....»»
The Zacks Analyst Blog Highlights: Walmart, NVIDIA, AstraZeneca, Goldman Sachs and Global Payments
Zacks.....»»
Eli Lilly Suffers Setback As Alzheimer"s Study Fails To Meet Primary Endpoint
Eli Lilly And Co (NYSE: LLY) shares were losing ground Monday following an announcement concerning the result of a Phase 2/3 study of an experimental Alzheimer's drug. 0 read more.....»»
Eli Lilly, Roche slide after Alzheimer"s drug fails to meet endpoint in study
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Biogen"s Alzheimer"s Drug Has "Decent Shot" At FDA Approval, Analyst Says
Despite the controversy surrounding Biogen Inc's (NASDAQ: BIIB).....»»
The Zacks Analyst Blog Highlights: Pfizer, Wells Fargo, SAP, salesforce.com and Eli Lilly
Zacks.....»»
Eli Lilly, AstraZeneca’s Alzheimer’s Drug Flop Is the Latest Disappointment in a Frustrating Disease
The story of Alzheimer's drug development is.....»»